All Updates

All Updates

icon
Filter
Funding
Black Diamond Therapeutics launches Launchpad Therapeutics; raises USD 30 million in Series A
Precision Medicine
Dec 12, 2022
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Dec 12, 2022

Black Diamond Therapeutics launches Launchpad Therapeutics; raises USD 30 million in Series A

Funding

  • Precision oncology company Black Diamond Therapeutics has launched a new company called Launchpad Therapeutics that will focus on developing antibody programs. Furthermore, Launchpad has raised USD 30 million in a Series A funding round from founding investors Versant Ventures and New Enterprise Associates. 

  • Black Diamond Therapeutics will receive a minority stake in Launchpad in exchange for its early discovery-stage antibody programs and a license to use its proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine for large molecule therapeutics. The spin-off will allow Black Diamond Therapeutics to focus on BDTX-1535, BDTX-4933, and its small molecule pipeline. 

  • Launchpad will focus on discovering, developing, and commercializing early mutant selective antibody drugs to treat oncology and immunology conditions. The company will use AI and the MAP platform to develop drugs targeting monoclonal antibodies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.